Head to Head Survey: JanOne (NASDAQ:JAN) and Galmed Pharmaceuticals (NASDAQ:GLMD)

Galmed Pharmaceuticals (NASDAQ:GLMD) and JanOne (NASDAQ:JAN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Galmed Pharmaceuticals and JanOne’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$6.91 million	($3.26)	-0.11
JanOne	$39.61 million	0.94	-$7.81 million	N/A	N/A

Galmed Pharmaceuticals has higher earnings, but lower revenue than JanOne.

Profitability

This table compares Galmed Pharmaceuticals and JanOne’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-53.29%	-44.35%
JanOne	N/A	-177.90%	-55.98%

Volatility and Risk

Galmed Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, JanOne has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Galmed Pharmaceuticals and JanOne, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	0	0	1	0	3.00
JanOne	0	0	0	0	N/A

Insider & Institutional Ownership

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 6.3% of JanOne shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of JanOne shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Galmed Pharmaceuticals beats JanOne on 6 of the 8 factors compared between the two stocks.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

About JanOne

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.